Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Activated dendritic cells delivered in tissue compatible biomatrices induce in-situ anti-tumor CTL responses leading to tumor regression.

Oncotarget - 28 Jun 2016

Verma Vivek, Kim Young, Lee Min-Cheol, Lee Jae-Tae, Cho Sunghoon, Park In-Kyu, Min Jung Joon, Lee Je Jung, Lee Shee Eun, Rhee Joon Haeng

Abstract excerpt

Dendritic cell (DC) based anti-cancer immunotherapy is well tolerated in patients with advanced cancers. However, the clinical responses seen after adoptive DC therapy have been suboptimal. Several factors including scarce DC numbers in tumors and immunosuppressive tumor microenvironments contribute to the inefficacy of DCs as cellular vaccines. Hence DC based vaccines can benefit from novel methods of cell...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigens, Neoplasm
Share to Cancer Vaccines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Coculture Techniques

Share to Immunosuppressive Agents

Share to Immunotherapy

Share to Melanoma, Experimental

Share to Spleen

Share to T-Lymphocytes, Cytotoxic

Source

Open in PubMed Open full text

Identifiers

PMID: 27223090
DOI: 10.18632/oncotarget.9529
PMCID: PMC5129979

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Activated dendritic cells delivered in tissue compatible biomatrices induce in-situ anti-tumor CTL responses leading to tumor regression.PMID 27223090Read ↗

Nanostructured Biomaterials in Tumor Tissue Engineering: Regenerative Medicine and ImmunotherapiesSemantic proximity Read ↗

Neoantigen enriched biomimetic nanovaccine for personalized cancer immunotherapySemantic proximity Read ↗

Targeting human dendritic cells in situ to improve vaccines.Semantic proximity Read ↗

Enhancing Dendritic Cell Cancer Vaccination: The Synergy of Immune Checkpoint Inhibitors in Combined TherapiesSemantic proximity Read ↗

Fibroblasts drive differential response in immunotherapy via IL-6 in bioengineered 3D cancer constructsSemantic proximity Read ↗

Optimized mobilization of MHC class I- and II- restricted immunity by dendritic cell vaccine potentiates cancer therapySemantic proximity Read ↗

Equipping Cancer Cell Membrane Vesicles with Functional DNA as a Targeted Vaccine for Cancer ImmunotherapySemantic proximity Read ↗

Dendritic cell vaccines in melanoma: from promise to proof?Semantic proximity Read ↗

Development of Cell Technologies Based on Dendritic Cells for Immunotherapy of Oncological DiseasesSemantic proximity Read ↗

Genetically Engineered Cytomembrane Nanovaccines for Cancer ImmunotherapySemantic proximity Read ↗

Rewiring dendritic cell function with CLEC9A and DEC205-based chimeric antigen receptorsSemantic proximity Read ↗

In situ vaccination using unique TLR9 ligand K3-SPG induces long-lasting systemic immune response and synergizes with systemic and local immunotherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.